Explore
Upload

DocSlides is a free service to upload presentations and documents.

Upload Now

Search Results for 'Pfs Fulvestrant'

Pfs Fulvestrant published presentations and documents on DocSlides.

BELLE-3: A Phase III Study of

BELLE-3: A Phase III Study of

  • faustina-dinatale
  • 0 Slides

Buparlisib. and . Fulvestrant. in Postmenopausa...

Jointly provided by & This activity is supported by educations grants from Novartis Pharmaceuticals Corporation, Pfizer, and Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com

Jointly provided by & This activity is supported by educations grants from Novartis Pharmaceuticals Corporation, Pfizer, and Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com

  • olivia-moreira
  • 67 Slides

Jointly provided by ...

Fulvestrant 500 mg versus

Fulvestrant 500 mg versus

  • elena
  • 30 Slides

anastrozole. as first-line treatment for advanced...

Module 8: ER-Positive Metastatic

Module 8: ER-Positive Metastatic

  • anastasia
  • 50 Slides

Breast Cancer . Elizabeth O’Reilly, MSN, MPH, AN...

Her-2 negative MBC

Her-2 negative MBC

  • conchita-marotz
  • 47 Slides

10/25/2016. Objectives. General principles. Endoc...

Median PFS: 2.6 months (95% CI, 1.7-3.5)

Median PFS: 2.6 months (95% CI, 1.7-3.5)

  • ceila
  • 5 Slides

Median PFS: 1.4 months (95% CI, 1.2-1.6) . Median ...

Targeting endocrine-resistance pathways in breast cancer

Targeting endocrine-resistance pathways in breast cancer

  • alexa-scheidler
  • 48 Slides

Targeting endocrine-resistance pathways in breas...

Endocrine resistance: molecular pathways and rational development of targeted therapies

Endocrine resistance: molecular pathways and rational development of targeted therapies

  • spottletoefacebook
  • 66 Slides

Grazia Arpino. Università di Napoli Federico II. ...

CDK4-6 INHIBITORS IN Breast Cancer: Optimal Treatment Sequencing

CDK4-6 INHIBITORS IN Breast Cancer: Optimal Treatment Sequencing

  • leah
  • 28 Slides

Mansoor A Khan, BS, MS, BCOP. Oncology/Hematology/...

Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor

Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor

  • byrne
  • 18 Slides

Overall survival and updated progression-free surv...

Beyond Secret Handshakes:

Beyond Secret Handshakes:

  • pasty-toler
  • 31 Slides

Affiliation-Hiding Authenticated Key Exchange. Fr...

2014 Oklahoma Business Summit

2014 Oklahoma Business Summit

  • marina-yarberry
  • 10 Slides

Sarah Roberts, Inasmuch Foundation, Program Offic...

Thierry Le Chevalier, MD

Thierry Le Chevalier, MD

  • yoshiko-marsland
  • 55 Slides

How . d. o International Regulatory Groups View C...

Partnerships for Success

Partnerships for Success

  • test
  • 28 Slides

Creating Positive School Experiences And Develop...

Ray Jones

Ray Jones

  • danika-pritchard
  • 37 Slides

Director of Solutions Architecture and Field Enab...

Blinded Sample Size Re-estimation in a Phase III Study Inve

Blinded Sample Size Re-estimation in a Phase III Study Inve

  • luanne-stotts
  • 27 Slides

David Morgan (King’s College, London / Consulta...

Thierry Le Chevalier, MD

Thierry Le Chevalier, MD

  • aaron
  • 53 Slides

How . d. o . International Regulatory Groups View...

Applying “Pay for Success” Social Impact Finance to Ear

Applying “Pay for Success” Social Impact Finance to Ear

  • luanne-stotts
  • 16 Slides

Janis Dubno, Voices for Utah Children. Andrea Phi...

Interpretation of the Great Plains Polygonal Fault

Interpretation of the Great Plains Polygonal Fault

  • luanne-stotts
  • 0 Slides

Andy St-Onge, Calgary geophysicist@shaw.ca. (i) S...

Btk inhibition in Mantle cell Lymphoma & CLL

Btk inhibition in Mantle cell Lymphoma & CLL

  • test
  • 0 Slides

Simon Rule. Professor of Clinical . Haematology. ...

Managing Advanced Renal Cell

Managing Advanced Renal Cell

  • debby-jeon
  • 0 Slides

Carcinoma: Balancing . Efficacy with Quality of L...

End-points utilized in

End-points utilized in

  • marina-yarberry
  • 10 Slides

End-points utilized in breast cancer clinical ...

Game Plan Trends in ovarian cancer

Game Plan Trends in ovarian cancer

  • alexa-scheidler
  • 59 Slides

Diagnostic work-up. Treatment. The most commonly ...

Nouveautés dans le CBNPC métastatique

Nouveautés dans le CBNPC métastatique

  • vizettan
  • 98 Slides

Celine Mascaux, MD, . PhD. Multidisciplinary . Onc...

Presentation

Presentation

  • wang
  • 1 Slides

pfs-full-vlSchema Taxo Fullwith capitalpfs-fullPre...

2022 Spring Oncology Conference

2022 Spring Oncology Conference

  • byrne
  • 62 Slides

Evolving Treatment Strategies. for CLL/SLL and MCL...

Update on Diagnosis and Treatments

Update on Diagnosis and Treatments

  • joanne
  • 29 Slides

of Multiple Myeloma. Kenneth C. Anderson, M.D.. J...

ESMO 2021 (Virtual) Congress Report

ESMO 2021 (Virtual) Congress Report

  • SnuggleBug
  • 122 Slides

Lung and gastrointestinal cancers. Slide numbers. ...

Considerations for Optimizing Transplant in Multiple Myeloma Patient Management

Considerations for Optimizing Transplant in Multiple Myeloma Patient Management

  • TravelingSoulmate
  • 77 Slides

PARAMESWARAN HARI MD. MEDICAL COLLEGE OF WISCONSIN...

Blinded Sample Size Re-estimation in a Phase III Study Investigating Progression Free Survival

Blinded Sample Size Re-estimation in a Phase III Study Investigating Progression Free Survival

  • naomi
  • 27 Slides

David Morgan (King’s College, London / Consultan...

Summary 2011 Founded 2010

Summary 2011 Founded 2010

  • eliza
  • 13 Slides

in Houston. Vision: To be the leader in the develo...

YIR On Demand Lung Benjamin Levy, MD 

YIR On Demand Lung Benjamin Levy, MD 

  • jovita
  • 84 Slides

Assistant Professor. Johns Hopkins School of Medic...

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Ref

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Ref

  • willow
  • 15 Slides

Meletios Dimopoulos,. 1. Hang Quach,. 2. Maria-V...

Concomitant administration of palbociclib and proton pump inhibitors affects clinical outcomes in m

Concomitant administration of palbociclib and proton pump inhibitors affects clinical outcomes in m

  • felicity
  • 1 Slides

Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor...

End-points utilized in breast cancer

End-points utilized in breast cancer

  • evelyn
  • 10 Slides

clinical . trials - Discussion. Novartis Oncology...

Pay for Success: Innovative Financing to Improve Child Outcomes

Pay for Success: Innovative Financing to Improve Child Outcomes

  • dominic513
  • 20 Slides

Jennifer Tschantz; Early Childhood Research to Pra...

Hormone Receptor-Positive Advanced Breast Cancer:

Hormone Receptor-Positive Advanced Breast Cancer:

  • min-jolicoeur
  • 0 Slides

HR Advanced Breast Cancer:. Introduction. Case S...

The Nurse View: Hormone Receptor-Positive Advanced Breast Cancer

The Nurse View: Hormone Receptor-Positive Advanced Breast Cancer

  • min-jolicoeur
  • 0 Slides

HR Advanced Breast Cancer. Introduction. Restagi...

Hormone Receptor Positive Metastatic Breast Cancer

Hormone Receptor Positive Metastatic Breast Cancer

  • pamella-moone
  • 80 Slides

. 5/9/2017. The Lancet July 11, 1895. ON THE TRE...

Endocrine Treatment of Metastatic Breast Cancer: New Advances; Patient Education Implications

Endocrine Treatment of Metastatic Breast Cancer: New Advances; Patient Education Implications

  • calandra-battersby
  • 74 Slides

An Interactive Oncology Grand Rounds Series. Joyc...

Copyright © 2024 DocSlides. All Rights Reserved